Reading Time: < 1 minute

WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX)
today announced that the Company will release its 2019 first quarter
financial results on Tuesday, May 7, 2019, before the market opens.

Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial
Officer, will host a conference call to discuss the results as follows:

Date   Tuesday, May 7, 2019

8:30 a.m. EDT

Toll free (U.S.) 877-876-9176
International 785-424-1670
Webcast (live and replay),
under the “Investor Relations” section

A replay of the conference call will be available for one week after the
call’s completion by dialing 800-839-5493 (US) or 402-220-2552
(International) and entering conference call ID EGRXQ119. The webcast
will be archived for 30 days at the aforementioned URL.

About Eagle Pharmaceuticals, Inc.

Eagle is a specialty pharmaceutical company focused on developing and
commercializing injectable products that address the shortcomings, as
identified by physicians, pharmacists and other stakeholders, of
existing commercially successful injectable products. Eagle’s strategy
is to utilize the FDA’s 505(b)(2) regulatory pathway. Additional
information is available on the company’s website at


Investor Relations for Eagle Pharmaceuticals, Inc:
Lisa M.
T: 212-452-2793
E: [email protected]